Background {#Sec1}
==========

Temporomandibular pain disorder (TMD) is a common pain condition in the face, with a prevalence of 5--33 % \[[@CR1], [@CR2]\]. TMD includes pain in the temporomandibular joint, disc, and surrounding muscles \[[@CR3]\]. People with TMD report multiple pain comorbidities \[[@CR4], [@CR5]\]. The presence of widespread pain is associated with onset and increase of TMD pain intensity, duration, and disability \[[@CR6]--[@CR10]\]. However, data on the relationship between TMD pain and multiple pain comorbidities that are not widespread is rare \[[@CR11]\]. Widespread pain may not be a good indicator of multiple pain comorbidities since it tends to be more severe, longer lasting, and accompanied by decreased functionality and poorer general health \[[@CR12]\]. Therefore, additional research is necessary to understand the relationship between multiple comorbidities and TMD pain intensity and duration.

Recent research in other pain conditions has revealed that some comorbidities interact with pain in more harmful ways. For example, having heart disease, depression, or anxiety increased the odds of having pain 5 years after total knee replacement by over 1.5 times, whereas having diabetes or renal disease did not \[[@CR13]\]. In people with TMD, the presence of migraine and fibromyalgia is associated with an increased TMD pain and disability \[[@CR6], [@CR7], [@CR14]--[@CR17]\]. However, there are few data of whether other comorbidities are associated with TMD pain intensity or duration.

In addition, people with myofascial TMD (m-TMD) have been observed to have more severe and longer-lasting pain, and experience more dysfunction and disability when compared to people with non-myofascial TMD (j-TMD) \[[@CR18]\]. However, it is unknown whether people with m-TMD exhibit differences in the relationships between number and specific comorbidities and TMD pain.

This study had three aims: Firstly, to describe the relationship between the number of comorbidities and TMD pain duration and intensity. We hypothesized that the number of comorbidities would be positively associated with levels of TMD pain intensity and duration. Secondly, we aimed to observe the association of five specific comorbidities and TMD pain duration and intensity. The presence of migraine was hypothesized to be associated with an increased TMD pain intensity and duration because of past studies indicating this relationship \[[@CR15], [@CR16]\]. No hypothesis was made for the other conditions since no prior data are available. Finally, we aimed to dichotomize participants into two TMD groups: m-TMD and j-TMD to test if the above associations remain the same for both TMD groups. We hypothesized that the same relationship would be observed in both groups.

Methods {#Sec2}
=======

Ethical approval to perform the study was granted from the Institutional Review Boards of McGill University and the Massachusetts General Hospital before the start of data collection. A written informed consent form was obtained from all participants prior to joining the study. This cross-sectional multi-center study included patients with TMD treated in three clinics: The Division of Dentistry at the Montreal General Hospital, the Department of Oral and Maxillofacial Surgery and Orofacial Pain Clinic at the Massachusetts General Hospital. At the Massachusetts General Hospital patients that fulfilled the inclusion criteria were approached during routine clinic visits and were invited to participate. At the Montreal General Hospital, inactive patients of a TMD clinic that had since been closed that were deemed eligible by a chart-review were invited to join the study by a letter mailed to their last known address. Patients with chronic TMD, lasting for more than 6 months, were included in the study \[[@CR19]\]. Excluded were patients with acute pain, other types of comorbid orofacial pain condition (neuropathic, burning mouth syndrome, atypical) and a history of TMJ surgery. Eligible participants who agreed to participate were diagnosed with TMD by a clinical exam using the Research Diagnostic Criteria (RDC/TMD) \[[@CR20]\] by two experienced dentists. The Kappa score between the two clinicians was considered good (0.88, 95 % CI 0.65-1.00) \[[@CR21]\]. The sample size was calculated for a linear regression model with an effect size between the outcome variables and predictor variable that is deemed as medium (F^2^ = 0.15), and a maximum number of predictors of 6 (the primary predictor variable, two known confounders like age and sex and three other potential confounders) \[[@CR22]\]. A sample of 97 was deemed necessary for a significance level of 0.05 and power at 80 %.

Data collection {#Sec3}
---------------

The current study assessed the following variables: TMD pain intensity and duration as outcome variables, and presence and number of specific comorbidities as exposure variables. The comorbidities were migraine, chronic fatigue syndrome (CFS), irritable bowel syndrome (IBS), interstitial cystitis (IC), and restless leg syndrome (RLS), all more prevalent in people with TMD than the general population \[[@CR4]\]. To assess the presence of specific comorbidities, each participant completed 5 validated diagnostic questionnaires: the ID Migraine \[[@CR23]\], the Schedule of Fatigue and Anergia \[[@CR24]\], the ROME III \[[@CR25]\], the Pain, Urgency and Frequency Symptom Scale \[[@CR26]\], and the Cambridge-Hopkins Restless Leg Syndrome Questionnaire-short form \[[@CR27]\]. These questionnaires all have very good sensitivity (range 81 % to 93 %), specificity (range 70 % to 95 %), and positive predictive value (range 70 to 94 %). Participants also completed a study questionnaire that assessed sociodemographic information and history of depression and anxiety. To assess the outcome variables, the duration of TMD pain was assessed in the study questionnaire by asking, "How long have you had pain in the face?" Average current TMD pain intensity was assessed by the Numerical Pain Rating Scale \[[@CR28]\] from 0 to 10.

Subjects were stratified into two TMD subgroups based on the presence of myofascial pain: m-TMD were participants who had myofascial pain, whether alone or in combination with other forms of TMD disorder; j-TMD were participants who were free of myofascial pain, but had other forms of TMD disorder. For the current study, m-TMD corresponded to the RDC/TMD group I (myofascial pain) alone, or in combination with group II (disc displacement) and/or group III (other joint conditions) and j-TMD corresponded to the RDC/TMD group II (disc displacement) and/or group III (other joint conditions).

Data analysis {#Sec4}
-------------

In order to reveal possible confounders, socio-demographic differences were compared between participants with and without comorbidities. Means and frequencies were used for continuous and categorical variables respectively. Differences in socio-demographic variables were tested using *T*-test for continuous variables and Chi-squared test for categorical variables. The selection of potential confounder included both a priori and empirical considerations. For empirical evidence, we included the covariates with a p-value equal to or less than 0.25 as confounders \[[@CR29]\]. A test for co-linearity between the exposure variables was also completed using variance inflation factor (VIF) larger than 10 as evidence of co-linearity between two exposure variables.

To analyze the relationships between the number of comorbidities present and the two outcome variables (TMD pain intensity and duration) and between specific comorbidities and the two outcome variables (TMD pain intensity and duration), multivariate linear regression analyses were done taking into account the confounding variables. For each outcome variable, three models of regression were performed: 1) Crude Model with no confounding variables, 2) Complete Model including all potential confounders and 3) Simple Model including only confounders that met the change-of-estimate criterion set at 20 % \[[@CR30]\].

Finally, we dichotomized the participants based on presence of myofascial pain (m-TMD and j-TMD) and re-ran the regression models to reveal the relationship of comorbidities and outcome variables based on TMD subgroups. Linear regression coefficient, the 95 % confidence intervals, p value and R^2^ values were estimated in all analyses. Statistical analyses were performed using Stata (version 10).

Results {#Sec5}
=======

A total of 224 participants agreed to partake in the study, of which 209 participants were from the Massachusetts General Hospital and 15 were from the Montreal General Hospital. Forty-four subjects were excluded from the study: 31 for not fulfilling the inclusion criteria and 13 for not completing all questionnaires. A final sample of 180 people completed the study. The final sample of 180 participants completed the study, which 68 (37.8 %) had no comorbidities, 54 (30.0 %) had one comorbidity and 58 (32.2 %) had at least two comorbidities (Table [1](#Tab1){ref-type="table"}). Participants with and without comorbidities differed in some of the socio-demographic characteristics: subjects with comorbidities displayed a more severe and longer duration of TMD pain and were more likely to have m-TMD, have a positive history of depression and/or anxiety and differ in work status.Table 1Socio-demographic characteristics of the study participantsVariablesNo comorbidityWith comorbidityP value(n = 68)(n = 112)Age, mean years (SD)44.77 (15.6)41.59 (15.3)0.18Female gender, n (%)52 (76.5)97 (86.6)0.08Marital Status, n (%)0.08Single17 (25.0)46 (41.1)Married43(63.2)49 (43.8)Divorced6 (8.8)14 (12.5)Widowed2 (2.9)3 (2.7)M-TMD n (%)37 (54.4)84 (75.9)\<0.01Pain intensity, mean (SD)4.57 (2.7)5.43 (2.3)0.03Pain Duration, mean years (SD)4.50 (6.9)7.44 (8.5)0.02Positive history of depression and/or anxiety, n (%)30 (44.1)70(62.5)0.02Work Status, n (%)0.02Unemployed11 (16.7)33 (29.5)On disability1 (1.5)11 (9.8)Part-time17 (25.0)15 (13.4)Full-time39 (57.3)53 (47.3)Education Status, n (%)0.85Did not finish high school4 (5.8)5 (4.5)Finished high school14 (20.6)22 (19.6)Attended some college50 (73.5)84 (75.0)Comorbidities, n (%)068 (100)154 (48.2)230 (26.8)319 (17.0)4+9 (8.0)Type of comorbidity, n (%)MigraineN/A83 (46.1)IBS51 (28.3)RLS30 (16.7)CFS26 (14.4)IC22 (12.2)

The covariate analysis for outcome variable, TMD pain duration, revealed that the confounders were sex, TMD group, marital status, work status and psychological history. Age was not found to be significant as a confounder but was included in the regression model due to the overwhelming evidence from previous research of the association with the chosen variables \[[@CR31]\]. The covariate analysis for outcome variable, TMD pain intensity, revealed that the confounders were TMD group, work status and psychological history. Sex and age were included in the regression model from previous research of the association with our variables \[[@CR31]\]. The test for co-linearity revealed that the exposure variable - the number of comorbidities, was highly correlated with the five tested comorbidities (VIF = 94). This result is not surprising, since the presence or absence of the five comorbidities in a participant defined his/her number of comorbidities (0 to 5).

Our analyses demonstrated a positive association between the number of comorbidities and TMD pain intensity in a dose--response fashion (Fig. [1](#Fig1){ref-type="fig"}). A positive association was also found between the number of comorbidities and TMD pain duration (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1The association between TMD pain intensity (0--10) and the number of comorbidities in all TMD participants (n = 180)Fig. 2The association between TMD pain duration (years) and the number of comorbidities in all TMD participants (n = 180)

Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} show the result of the linear regression analysis comparing TMD pain duration and intensity as outcome variables. After controlling for confounding variables there was a significant association between the number of comorbidities and TMD pain duration in all three regression models. As well, there was an association between the number of comorbidities and TMD pain intensity in all three models. The regression models of specific comorbidities indicated that the presence of CFS had the strongest association with both TMD pain duration and intensity. The presence of migraine was associated with a one-point increase in TMD pain intensity. The other comorbidities were not associated with either TMD pain intensity or duration.Table 2Results of multiple linear regression models comparing between comorbidities and TMD pain duration in the combined TMD group (n = 180)Outcome variablesExposure variablesCrude ModelComplete modelSimple modelCoefficient (95 % CI)Coefficient (95 % CI)Coefficient (95 % CI)p value, r^2^ valuep value, r^2^ valuep value, r^2^ valueTMD duration (years)Number of comorbidities1.73 (0.78 -- 2.68)1.64 (0.62 -- 2.65)1.56 (0.59 -- 2.53)p \< 0.01, r^2^ = 0.06p \< 0.01, r^2^ = 0.13p \< 0.01, r^2^ = 0.13Migraine1.56 (−0.83 -- 3.95)0.28 (−2.31 -- 2.87)0.01 (−2.47 -- 2.49)p = 0.20, r^2^ = 0.01p = 0.83, r^2^ = 0.17p = 0.99, r^2^ = 0.16Chronic Fatigue Syndrome6.58 (3.32 -- 9.84)6.03 (2.52 -- 9.54)5.84 (2.38 -- 9.30)p \< 0.01, r^2^ = 0.08p \< 0.01, r^2^ = 0.17p \< 0.01, r^2^ = 0.16Irritable Bowel Syndrome3.03 (0.42 -- 5.65)2.24 (−0.41 -- 4.90)2.15 (−0.47 -- 4.77)p = 0.02, r^2^ = 0.03p = 0.10, r^2^ = 0.17p = 0.11, r^2^ = 0.16Interstitial Cystitis4.04 (0.44 -- 7.64)0.71 (−3.17 -- 4.59)0.78 (−3.03 -- 4.59)p = 0.03, r^2^ = 0.03p = 0.72, r^2^ = 0.17p = 0.69, r^2^ = 0.16Restless Leg Syndrome1.68 (−1.52 -- 4.87)−0.16 (−3.39 -- 3.07)−0.15 (−3.35 -- 3.04)p = 0.30, r^2^ = 0.01p = 0.92, r^2^ = 0.17p = 0.92, r^2^ = 0.16Table 3Results of multiple linear regression models comparing between comorbidities and TMD pain intensity in the combined TMD group (n = 180)Outcome variablesExposure variablesCrude ModelComplete modelSimple modelCoefficient (95 % CI)Coefficient (95 % CI)Coefficient (95 % CI)p value, r^2^ valuep value, r^2^ valuep value, r^2^ valueTMD intensity (0--10)Number of comorbidities0.57 (0.27 -- 3.95)0.46 (0.14 -- 0.78)0.46 (0.15 -- 0.78)p \< 0.01, r^2^ = 0.07p \< 0.01, r^2^ = 0.10p \< 0.01, r^2^ = 0.10Migraine1.43 (0.71 -- 2.15)1.02 (0.20 -- 1.84)1.08 (0.30 -- 1.87)p \< 0.01, r^2^ = 0.08p \< 0.05, r^2^ = 0.15p \< 0.01, r^2^ = 0.14Chronic Fatigue Syndrome1.85 (0.83 -- 2.88)1.07 (−0.03 -- 2.19)1.12 (0.03 -- 2.22)p \< 0.01, r^2^ = 0.07p = 0.06, r^2^ = 0.15p \< 0.05, r^2^ = 0.14Irritable Bowel Syndrome0.66 (−0.167 --1.48)0.10 (−0.73 -- 0.94)0.10 (−0.73 -- 0.93)p = 0.12, r^2^ = 0.01p = 0.81, r^2^ = 0.15p = 0.81, r^2^ = 0.14Interstitial Cystitis1.40 (0.28 --2.52)0.85 (−0.36 -- 2.07)0.86 (−0.34 -- 2.07)p = 0.01, r^2^ = 0.03p = 0.16, r^2^ = 0.15p = 0.16, r^2^ = 0.14Restless Leg Syndrome−0.21 (−1.21 -- 0.79)−0.87 (−1.89 -- 0.15)−0.90 (−1.91 -- 0.11)p = 0.68, r^2^ = 0.001p = 0.09, r^2^ = 0.15p = 0.08, r^2^ = 0.14

Finally, we dichotomized the participants based on the presence of m-TMD and re-ran the regression models to reveal the relationship of comorbidities and our outcome variables based on TMD subgroups. Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} show that the associations in the combined TMD group held true for the m-TMD subgroup. However, Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"} indicate that in the j-TMD group, the only association observed was between the number of comorbidities and TMD pain duration. All other associations observed in the combined TMD group did not meet statistical significance in the j-TMD subgroup.Table 4Results of multiple linear regression models between comorbidities and TMD pain duration in participants in the m-TMD group (n = 121)Dependent variablesIndependent variablesCrude ModelComplex modelSimple modelCoefficient (95 % CI)Coefficient (95 % CI)Coefficient (95 % CI)p value, r^2^ valuep value, r^2^ valuep value, r^2^ valueTMD duration (years)Number of comorbidity1.51 (0.35 -- 2.66)1.53 (0.33 -- 2.73)1.44 (0.25 -- 2.62),p \< 0.05, r^2^ = 0.05p \< 0.05, r^2^ = 0.07p \< 0.05, r^2^ = 0.11Migraine1.11 (−1.72 -- 3.94)0.34 (−2.60 -- 3.28)−0.01 (−2.89 --2.87)p = 0.44, r^2^ = 0.01p = 0.82, r^2^ = 0.18p = 0.99, r^2^ = 0.17Chronic Fatigue Syndrome5.38 (1.91 -- 8.84),5.98 (2.16 -- 9.79),5.54 (1.78 -- 9.30),p \< 0.01, r = 0.07p \< 0.01, r^2^ = 0.18p \< 0.01, r^2^ = 0.17Irritable Bowel Syndrome3.08 (0.06 -- 6.09)3.14 (0.04 -- 6.25)3.14 (0.04 -- 6.23)p = 0.05, r^2^ = 0.03p = 0.05, r^2^ = 0.18p = 0.05, r^2^ = 0.17Interstitial Cystitis2.04 (−2.01 -- 6.09)−0.88 (5.17 -- 3.42)−0.71 (−4.98 -- 3.56)p = 0.32, r^2^ = 0.01p = 0.69, r^2^ = 0.18p = 0.74, r^2^ = 0.17Restless Leg Syndrome−0.23 (−4.03 -- 3.56)−1.74 (−5.54 -- 2.07)−1.69 (−5.47 -- 2.09)p = 0.90, r^2^ = 0.001p = 0.37, r^2^ = 0.18p = 0.38, r^2^ = 0.17Table 5Results of multiple linear regression models between comorbidities and TMD pain intensity in participants in the m-TMD group (n = 121)Dependent variablesIndependent variablesCrude ModelComplex modelSimple modelCoefficient (95 % CI)Coefficient (95 % CI)Coefficient (95 % CI)p value, r^2^ valuep value, r^2^ valuep value, r^2^ valueTMD intensity (0--10)Number of comorbidity0.63 (0.31 -- 0.95),0.60 (0.25 -- 0.94),0.62 (0.27 -- 0.95),p \< 0.01, r^2^ = 0.11p \< 0.01, r^2^ = 0.13p \< 0.01, r^2^ = 0.13Migraine1.45 (0.64 -- 2.25),1.08 (0.21 -- 1.95),1.08 (0.23 -- 1.93),p \< 0.01, r^2^ = 0.10p \< 0.05, r^2^ = 0.18p \< 0.05, r^2^ = 0.18Chronic Fatigue Syndrome1.82 (0.81 -- 2.85),1.42 (0.29 -- 2.54),1.42 (0.30 -- 2.53),p \< 0.01, r^2^ = 0.10p \< 0.05, r^2^ = 0.18p \< 0.05, r^2^ = 0.18Irritable Bowel Syndrome0.36 (−0.56 -- 1.27)−0.05 (−0.97 -- 0.87)−0.05 (−0.97 -- 0.87)p = 0.44, r^2^ = 0.01p = 0.91, r^2^ = 0.18p = 0.91, r^2^ = 0.18Interstitial Cystitis1.36 (0.18 -- 2.55)0.71 (−0.56 -- 1.98)0.70 (−0.56 -- 1.97)p = 0.03, r^2^ = 0.04p = 0.27, r^2^ = 0.18p = 0.27, r^2^ = 0.18Restless Leg Syndrome0.61 (−0.51 -- 1.74)−0.12 (−1.25 -- 0.99)−0.13 (−1.24 -- 0.99)p = 0.28, r^2^ = 0.01p = 0.82, r^2^ = 0.18p = 0.82, r^2^ = 0.18Table 6Results of multiple linear regression models between comorbidities and TMD pain duration in participants in the j-TMD group (n = 59)Dependent variablesIndependent variablesCrude ModelComplex modelSimple modelCoefficient (95 % CI)Coefficient (95 % CI)Coefficient (95 % CI)p value, r^2^ valuep value, r^2^ valuep value, r^2^ valueTMD duration (years)Number of comorbidity2.77 (0.80 -- 4.73),2.54 (0.31 -- 4.77),2.38 (0.33 -- 4.44),p \< 0.01, r^2^ = 0.12p \< 0.05, r^2^ = 0.21p \< 0.05, r^2^ = 0.20Migraine2.43 (−2.59 -- 7.46)0.05 (−5.83 -- 5.93)0.39 (−5.40 -- 6.17)p = 0.34, r^2^ = 0.02p = 0.99, r^2^ = 0.26p = 0.89, r^2^ = 0.25Chronic Fatigue Syndrome14.90 (5.23 -- 24.55)8.20 (−4.20 -- 20.60),9.89 (−1.71 -- 21.48),p \< 0.05, r^2^ = 0.14p = 0.19, r^2^ = 0.26p = 0.09, r^2^ = 0.25Irritable Bowel Syndrome2.80 (−2.53 -- 8.14)0.69 (−5.36 -- 6.74)0.69 (4.96 -- 6.34)p = 0.30, r^2^ = 0.02p = 0.82, r^2^ = 0.26p = 0.81, r^2^ = 0.25Interstitial Cystitis10.20 (2.43 -- 17.98)5.58 (−4.99 --16.14)3.64 (−6.05 -- 13.33)p = 0.01, r^2^ = 0.11p = 0.29, r^2^ = 0.26p = 0.45, r^2^ = 0.25Restless Leg Syndrome5.52 (−0.40 -- 11.45)2.86 (−3.99 -- 9.70)2.30 (−4.20 -- 8.81)p = 0.07, r^2^ = 0.06p = 0.41, r^2^ = 0.26p = 0.48, r^2^ = 0.25Table 7Results of multiple linear regression models between comorbidities and TMD pain intensity in participants in the j-TMD group (n = 59)Dependent variablesIndependent variablesCrude ModelComplex modelSimple modelCoefficient (95 % CI)Coefficient (95 % CI)Coefficient (95 % CI)p value, r^2^ valuep value, r^2^ valuep value, r^2^ valueTMD intensity (0--10)Number of comorbidity0.24 (−0.44 -- 0.92)0.20 (−0.57 -- 0.97)0.12 (−0.59 -- 0.84)p = 0.49, r^2^ = 0.01p = 0.60, r^2^ = 0.09p = 0.73, r^2^ = 0.09Migraine0.99 (−0.64 -- 2.61)0.34 (−1.62 -- 2.32)0.34 (−1.67 -- 2.29)p = 0.23, r^2^ = 0.03p = 0.73, r^2^ = 0.19p = 0.73, r^2^ = 0.19Chronic Fatigue Syndrome0.84 (−2.54 -- 4.22)0.08 (−3.94 -- 4.09)−0.08 (−4.00 -- 3.82)p = 0.62, r^2^ = 0.004p = 0.97, r^2^ = 0.19p = 0.97, r^2^ = 0.19Irritable Bowel Syndrome1.17 (−0.55 -- 2.90)0.75 (−1.29 -- 2.79)0.59 (−1.31 -- 2.50)p = 0.18, r^2^ = 0.03p = 0.47, r^2^ = 0.19p = 0.53, r^2^ = 0.19Interstitial Cystitis1.16 (−1.50 -- 3.82)1.65 (1.66 -- 4.97)1.73 (−1.53 -- 5.01)p = 0.39, r^2^ = 0.01p = 0.32, r^2^ = 0.19p = 0.29, r^2^ = 0.19Restless Leg Syndrome−1.85 (−3.77 -- 0.08)−2.13 (4.42 -- 0.14)−2.26 (−4.46 -- −0.07)p = 0.06, r^2^ = 0.06p = 0.07, r^2^ = 0.19p = 0.04, r^2^ = 0.19

Discussion {#Sec6}
==========

In this cross-sectional study, more than 62 % of participants suffered from at least one comorbid condition, with migraine, IBS and RLS being the most prevalent. This percentage is similar to previous results, showing that 70 % of people with painful TMD had at least one comorbidity \[[@CR32]\]. Clearly, people with chronic TMD seeking treatment have a large overlap with other body pains. Compared to people without comorbidities, participants with comorbidities were more likely to be females with m-TMD, with a history of depression and/or anxiety and experiencing higher TMD pain intensity. These differences confirm earlier research, suggesting that the presence of comorbidities in patients with TMD may signify a more complex disorder \[[@CR5], [@CR7], [@CR33]--[@CR36]\].

Our study revealed a positive relationship between the number of comorbid conditions present and TMD pain duration and intensity. To our knowledge, our study is the first to look at this relationship using linear regression analyses, allowing control for other comorbid conditions and confounders. One previous study found a correlation between increasing number of pain symptoms and greater TMD pain severity \[[@CR37]\], while other studies have found higher TMD pain intensity in subjects with widespread pain, compared to subjects with localized pain \[[@CR7], [@CR38]\]. No previous study has looked at the association between TMD pain duration and increasing number of pain sites. However, previous studies exist looking at persistent TMD pain, which could be comparable to long duration of TMD pain. For example, a longitudinal study revealed that the number of bodily pain sites were positively associated with having a persistent TMD pain (pain after 5 years), compared to TMD patients in remission (no pain after 5 years), with odds of 1.81 \[[@CR11]\]. Other studies showed that baseline widespread pain was the most predictive factor for persistent TMD pain (OR = 1.78 - 1.99) \[[@CR6], [@CR39]\].

The relationship between the presence of comorbidities and TMD pain duration and intensity appear to be related to central sensitization \[[@CR40], [@CR41]\]. TMD patients with comorbidities have evidence of central sensitization and allodynia \[[@CR42], [@CR43]\], which may explain the increased TMD pain duration and intensity. As well, chronic TMD is associated with neural abnormalities in the trigeminal and limbic systems, which may be related to spreading of pain to other body parts \[[@CR44]\].

The results show that the presence of migraine was associated with an increased TMD intensity. Migraine is prevalent among TMD patients, with a prevalence of migraine 22--58 % \[[@CR45]--[@CR47]\] and it is associated with increased physical and psychosocial disability \[[@CR14]--[@CR17]\]. The association between migraine and increased TMD pain intensity has been observed in a prior study, where the relative risk of having moderate/severe TMD compared to mild TMD with migraine comorbidity was 7.8 \[[@CR47]\]. Furthermore, an association between frequency of headaches and TMD pain duration and intensity has been observed \[[@CR48]\]. We also show that CFS is associated with TMD pain intensity and duration. The association between CFS and TMD pain duration was exceptionally high, suggesting a more profound central sensitization \[[@CR49]\]. CFS is a condition that can overlap with TMD (20 %) \[[@CR50]\]. However, fibromyalgia (FM), a condition that overlaps with both TMD and CFS was not controlled for in our study \[[@CR49]\]. TMD patients with FM experience more intense and prolonged pain than TMD patients without FM \[[@CR49]\]. Therefore, it is possible that the influence of CFS on TMD pain intensity and duration was partially or fully mediated by the presence of FM. The other conditions, IBS, IC and RLS were not associated with either TMD pain intensity or duration. However, such association could have been found with a larger sample size; an ad-hoc sample size calculation revealed that the sample size would need to be 333 to statistically observe an association if the effect size was small (f^2^ = 0.05), based on the numbers of predictors that were used in the current study.

This study also shows a difference between the m-TMD and j-TMD groups, where the j-TMD group did not display strong associations between most outcome and exposure variables. This may support the notion that j-TMD disease does not involve central sensitization \[[@CR51]--[@CR53]\]. However, an association between migraine and both m-TMD and j-TMD has been previously observed \[[@CR54]\]. Since the sample size of j-TMD group was smaller than the m-TMD group (n = 59 vs. 121, respectively), the study may have been underpowered. Specifically, the regression results between CFS and TMD pain duration suggest that an association may exist but was not adequately detected.

This study has some limitations. Firstly, being a cross-sectional study, it cannot provide information regarding the direction of association between comorbidities and pain characteristics in TMD patients. Secondly, the subjects were people seeking treatment at a hospital center for TMD. They may not represent the average profile of a TMD patient, which has been shown to have acute, self-limiting pain \[[@CR55]\]. Therefore, our study results could be more generalizable for people with chronic TMD seeking treatment. Thirdly, the study focused on the impact of specific comorbidities on TMD pain characteristics without taking into account the intensity or duration of these disorders. Other possible limitations include relatively small sample size that could result in missing certain associations in the final analysis, measurement errors, particularly for pain duration. Finally, a measurement bias may exist since emotional distress and psychological status may not have been adequately assessed and controlled for all subjects \[[@CR56]\]. To assess psychological variables, patients were asked about a history of depression and anxiety, responding with a simple yes/no answer. A more accurate assessment could be done using a validated surveys like the Hospital Anxiety and Depression Scale \[[@CR57]\].

Conclusions {#Sec7}
===========

This study shows that in people with chronic TMD, increasing number of comorbid conditions was positively associated with TMD pain duration and intensity. Also, the presence of some conditions, such as migraine and CFS, are associated with increased TMD intensity and duration. These findings could be clinically relevant, suggesting that in order to improve TMD symptoms other existing comorbidities need to be assessed and addressed, probably in interdisciplinary clinics hosting multiple health professions \[[@CR55]\].

TMD

:   Temporomandibular disorder

CFS

:   Chronic fatigue syndrome

RLS

:   Restless leg syndrome

IC

:   Interstitial cystitis

FM

:   Fibromyalgia

VIF

:   variance inflation factor

m-TMD

:   Myofascial TMD

j-TMD

:   Non-myofascial TMD
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